GlassScriptPhysician profile
Melissa D Smith
NPI 1073839684
$2,673.78
in general payments reported to CMS, 2019-2025
15 companies · $877 in 2025
The $877 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $292 · 2023: $742 · 2024: $639 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,257.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $710.57 | 2021-2025 | Carto 3, Nuvision Ice Catheter |
| Abbvie INC. | $311.56 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $259.07 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $241.90 | 2021-2024 | Xarelto |
| Abbott Laboratories | $206.56 | 2022-2024 | Freestyle Libre 3, Proclaim |
| Novo Nordisk INC | $148.39 | 2023 | Novoseven |
| Kyowa Kirin, INC. | $139.99 | 2025 | |
| Paratek Pharmaceuticals, INC. | $125.00 | 2023 | Nuzyra |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
| Gilead Sciences, INC. | $97.13 | 2025 | Epclusa |
| Ucb, INC. | $82.87 | 2024 | Nayzilam |
| Corcept Therapeutics | $77.70 | 2024 | Korlym |
| Teva Pharmaceuticals USA, INC. | $68.24 | 2024 | Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $61.13 | 2025 | Wainua |
| Abiomed | $18.67 | 2024 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.